C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat
- 1 July 2001
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 44 (7) , 889-897
- https://doi.org/10.1007/s001250100570
Abstract
Aims/hypothesis. Insulin and C-peptide exert neuroprotective effects and are deficient in Type I (insulin-dependent) diabetes mellitus but not in Type II (non-insulin-dependent) diabetes mellitus. These studies were designed to test the preventive and interventional effects of C-peptide replacement on diabetic polyneuropathy in the Type I diabetic BB/Wor rat. Methods. Diabetic BB/Wor rats were replaced with rat C-peptide from onset of diabetes and between 5 and 8 months of diabetes. They were examined at 2 and 8 months and compared to non-C-peptide replaced BB/Wor rats, Type II diabetic (non-C-peptide deficient) BB/Z rats and non-diabetic control rats. Animals were monitored as to hyperglycaemia and nerve conduction velocity (NCV). Acute changes such as neural Na+/K+-ATPase and paranodal swelling were examined at 2 months, morphometric and teased fiber analyses were done at 8 months. Results. C-peptide replacement for 2 months in Type I diabetic rats prevented the acute NCV defect by 59 % (p < 0.005), the neural Na+/K+-ATPase defect by 55 % (p < 0.001) and acute paranodal swelling by 61 % (p < 0.001). Eight months of C-peptide replacement prevented the chronic nerve conduction defect by 71 % (p < 0.001) and totally prevented axoglial dysjunction (p < 0.001) and paranodal demyelination (p < 0.001). C-peptide treatment from 5 to 8 months showed a 13 % (p < 0.05) improvement in NCV, a 33 % (p < 0.05) improvement in axoglial dysjunction, normalization (p < 0.001) of paranodal demyelination, repair of axonal degeneration (p < 0.01), and a fourfold (p < 0.001) increase in nerve fibre regeneration. Conclusion/interpretation. C-peptide replacement of Type I BB/Wor-rats partially prevents acute and chronic metabolic, functional and structural changes that separate Type I diabetic polyneuropathy from its Type II counterpart suggesting that C-peptide deficiency plays a pathogenetic role in Type I diabetic polyneuropathy. [Diabetologia (2001) 44: 889–897]Keywords
This publication has 15 references indexed in Scilit:
- A comparison of diabetic polyneuropathy in Type II diabetic BBZDR/Wor rats and in Type I diabetic BB/Wor ratsDiabetologia, 2000
- Specific binding of proinsulin C-peptide to human cell membranesProceedings of the National Academy of Sciences, 1999
- Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort.Diabetes Care, 1999
- Experimental diabetic neuropathy: an updateDiabetologia, 1999
- Lesion-induced increase in nerve growth factor mRNA is mediated by c-fos.Proceedings of the National Academy of Sciences, 1990
- Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.Journal of Clinical Investigation, 1990
- Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.Journal of Clinical Investigation, 1988
- Axo-glial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat.Journal of Clinical Investigation, 1986
- Changes in nodal function in nerve fibres of the spontaneously diabetic BB‐Wistar rat: Potential clamp analysisActa Physiologica Scandinavica, 1981
- Insulin Biosynthesis: Evidence for a PrecursorScience, 1967